Following on from information provided to NICE by the company in March 2019, the appraisal of Ofatumumab (Arzerra) in combination with chemotherapy for follicular lymphoma; second line - refractory to rituximab [ID1487] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
 
Status Discontinued
Technology type Medicine
Decision Selected
Process TA
ID number 1487

Email enquiries

Timeline

Key events during the development of the guidance:

Date Update
31 October 2022 Discontinued. Following on from information provided to NICE by the company in March 2019, the appraisal of Ofatumumab (Arzerra) in combination with chemotherapy for follicular lymphoma; second line - refractory to rituximab [ID1487] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
21 November 2018 Suspended. The Department for Health and Social Care has asked NICE to conduct an appraisal of ofatumumab in combination with chemotherapy in patients with follicular lymphoma that is refractory to rituximab. However, the company have advised that they will not be pursuing a licensing application for ofatumumab from the European Medicines Authority for this indication at this time. Therefore, NICE has decided to suspend this appraisal on its work programme. As this appraisal has been referred to NICE we will continue to monitor any development and will update interested parties if the situation changes.
22 July 2016 Referral

For further information on our processes and methods, please see our CHTE processes and methods manual